Russell Perry, MD
Allergy & Immunology · Beaumont, TXNPI 1780770362
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Genentech USA, Inc. accounts for 65.4% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2019 at $22,620 and has fallen 84.7% since, to $3,452 in 2025. Among allergy & immunology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 672 payments — averaging $67.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$30K
- AstraZeneca$3K
- Pfizer$2K
- Amgen$2K
- GSK$1K
- Novartis$1K
- plus $7K from 34 others
Across 115 payments — averaging $27,871 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2.9M
- AbbVie$210K
- Modernatx, Inc.$132K
- Galderma Laboratories, L.p.$8K
What the payments were for
- Consulting fees$2,1355%
- Speaking & faculty fees$24,99055%
- Travel & lodging$2,4035%
- Food & beverage$15,52034%
- Education$1720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$45,219 in reported general payments places this provider in the 90th percentile of 336 allergy & immunology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 12 | $305,797 |
| Dupixent SyringeDupilumab | 11 | $62,410 |
| XolairOmalizumab | 17 | $56,124 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $45,214 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $7,595 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 17 | $4,033 |
| Epinephrine | 12 | $2,770 |
| Wixela InhubFluticasone Propion/Salmeterol | 15 | $1,157 |
| Montelukast Sodium | 71 | $671 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $338 |
| Prednisone | 58 | $224 |
| Fluticasone Propionate | 11 | $138 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $442 | $305,79712 claims |
| Genentech, Inc.Xolair | $85 | $56,12417 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,432 | $52,81063 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 336 allergy & immunology providers in Texas.
Other allergy & immunology in Beaumont
- Joseph DiazSan Antonio$1.1M
- Richard WassermanDallas$452K
- Matthew FeldmanDallas$410K
- Lukena KarkhanisSan Antonio$377K
- Paul VigoAustin$304K
- Neha ReshamwalaAustin$303K
- Lara GrossDallas$171K
- Bobby LanierBenbrook$149K
- Juan ZambranoHouston$146K
- Serge de GolovineBellaire$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.